Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine

被引:9
作者
Giarola-Silva, Sarah [1 ]
Coelho-dos-Reis, Jordana G. A. [1 ]
Mourao, Marina Moraes [2 ]
Campi-Azevedo, Ana Carolina [1 ]
Nakagaki Silva, Erick E. [2 ]
Luiza-Silva, Maria [3 ]
Martins, Marina Angela [1 ]
de Oliveira Silveira-Cassette, Amanda Cardoso [1 ]
Batista, Mauricio Azevedo [1 ]
Peruhype-Magalhaes, Vanessa [1 ]
do Valle Antonelli, Lis Ribeiro [4 ]
Leite Ribeiro, Jose Geraldo [5 ]
Eloi-Santos, Silvana Maria [1 ,3 ]
Machado, Alexandre Vieira [6 ]
Teixeira-Carvalho, Andrea [1 ]
Martins-Filho, Olindo Assis [1 ]
Silva Araujo, Marcio Sobreira [1 ]
机构
[1] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Integrado Pesquisas Biomarcadores, Belo Horizonte, MG, Brazil
[2] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Helmintol & Malacol Med, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
[4] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Biol & Imunol Parasitaria, Belo Horizonte, MG, Brazil
[5] Secretaria Estadual Saude Minas Gerais, Belo Horizonte, MG, Brazil
[6] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Imunol Doencas Virais, Belo Horizonte, MG, Brazil
关键词
H1N1; vaccine; AS03; adjuvant; Immune response; Biomarker signature; PANDEMIC H1N1 INFLUENZA; ADVERSE EVENTS; AS03; ADJUVANT; B-LYMPHOCYTES; CHILDREN; CYTOKINE; AGE; IMMUNOGENICITY; INTERLEUKIN-10; SIGNATURES;
D O I
10.1016/j.antiviral.2017.05.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4(+), CDS+ T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tIr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,1-6,1L-1 beta,1L-12,1-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-alpha/IL-12/IFN-gamma axis derived from NK-cells, CD4(+) and CD8(+) T-cells along with promiscuous production of IL-4/IL-5/1L-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-alpha and IL-4, with late IL-10 production by CD8(+) T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4(+)/CD8(+) T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:70 / 82
页数:13
相关论文
共 50 条
  • [21] A Prospective Study of the Factors Shaping Antibody Responses to the AS03-Adjuvanted Influenza A/H1N1 Vaccine in Cancer Outpatients
    Hottinger, Andreas F.
    George, Anne-Claude C.
    Bel, Michael
    Favet, Laurence
    Combescure, Christophe
    Meier, Sara
    Grillet, Stephane
    Posfay-Barbe, Klara
    Kaiser, Laurent
    Siegrist, Claire-Anne
    Dietrich, Pierre-Yves
    ONCOLOGIST, 2012, 17 (03) : 436 - 445
  • [22] Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis
    Sampaio-Barros, Percival D.
    Andrade, Danieli C. O.
    Seguro, Luciana C. P.
    Pasoto, Sandra G.
    Viana, Vilma S. T.
    Ribeiro, Ana C. M.
    Aikawa, Nadia E.
    Timenetsky, Maria do Carmo S.
    Precioso, Alexander R.
    Silva, Clovis A.
    Bonfa, Eloisa
    RHEUMATOLOGY, 2018, 57 (10) : 1721 - 1725
  • [23] Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients
    Miraglia, Joao L.
    Abdala, Edson
    Hoff, Paulo M.
    Luiz, Andre M.
    Oliveira, Danise S.
    Saad, Carla G. S.
    Laurindo, Ieda M. M.
    Viso, Ana T. R.
    Tayra, Angela
    Pierrotti, Ligia C.
    Azevedo, Luiz S.
    Campos, Lucia Maria A.
    Aikawa, Nadia E.
    Timenetsky, Maria do Carmo S. T.
    Luna, Expedito
    Cardoso, Maria Regina A.
    Guedes, Jose da S.
    Raw, Isaias
    Kalil, Jorge
    Precioso, Alexander R.
    PLOS ONE, 2011, 6 (11):
  • [24] Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases
    C. Sengler
    M. Niewerth
    T. Kallinich
    A. Nimtz-Talaska
    M. Haller
    H.-I. Huppertz
    K. Minden
    Clinical Rheumatology, 2014, 33 : 137 - 139
  • [25] Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
    Nolan, Terry
    Roy-Ghanta, Sumita
    Montellano, May
    Weckx, Lily
    Ulloa-Gutierrez, Rolando
    Lazcano-Ponce, Eduardo
    Kerdpanich, Angkool
    Palazzi Safadi, Marco Aurelio
    Cruz-Valdez, Aurelio
    Litao, Sandra
    Lim, Fong Seng
    Mascarenas de Los Santos, Abiel
    Rodriguez Weber, Miguel Angel
    Tinoco, Juan-Carlos
    Hernandez-de Mezerville, Marcela
    Faingezicht, Idis
    Kosuwon, Pensri
    Lopez, Pio
    Borja-Tabora, Charissa
    Li, Ping
    Durviaux, Serge
    Fries, Louis
    Dubin, Gary
    Breuer, Thomas
    Innis, Bruce L.
    Vaughn, David W.
    JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (04) : 545 - 557
  • [26] Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies
    Ide, Yuichiro
    Imamura, Yutaka
    Ohfuji, Satoko
    Fukushima, Wakaba
    Ide, Saburo
    Tsutsumi, Chiyo
    Koga, Masahisa
    Maeda, Kazuhiro
    Hirota, Yoshio
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (08) : 2387 - 2394
  • [27] Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children
    Kotloff, Karen L.
    Halasa, Natasha B.
    Harrison, Christopher J.
    Englund, Janet A.
    Walter, Emmanuel B.
    King, James C.
    Creech, C. Buddy
    Healy, Sara A.
    Dolor, Rowena J.
    Stephens, Ina
    Edwards, Kathryn M.
    Noah, Diana L.
    Hill, Heather
    Wolff, Mark
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (08) : 865 - 871
  • [28] Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 mo to 17 y of age
    Vesikari, Timo
    Pepin, Stephanie
    Kusters, Inca
    Hoffenbach, Agnes
    Denis, Martine
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (09) : 1283 - 1292
  • [29] Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents
    Garcia-Sicilia, J.
    Gillard, P.
    Carmona, A.
    Tejedor, J. C.
    Aristegui, J.
    Merino, J. M.
    Behre, U.
    Caplanusi, A.
    Vaman, T.
    Dieussaert, I.
    VACCINE, 2011, 29 (26) : 4353 - 4361
  • [30] Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
    Vaughn, David W.
    Seifert, Harry
    Hepburn, Anne
    Dewe, Walthere
    Li, Ping
    Drame, Mamadou
    Cohet, Catherine
    Innis, Bruce L.
    Fries, Louis F.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (10) : 2942 - 2957